Caribou Biosciences Inc 2026年季度报告

Caribou Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter)______________________________________ Registrant’s telephone number, including area code: (510) 982-6030______________________________________ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subjectto such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Table of Contents PART I.FINANCIAL INFORMATION1Item 1.Financial Statements (Unaudited)1Condensed Consolidated Balance Sheets1Condensed Consolidated Statements of Operations and Comprehensive Loss2Condensed Consolidated Statements of Stockholders’ Equity3Condensed Consolidated Statements of Cash Flows4Notes to Unaudited Condensed Consolidated Financial Statements5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations17Item 3.Quantitative and Qualitative Disclosures About Market Risk26Item 4.Controls and Procedures26PART II.OTHER INFORMATION27Item 1.Legal Proceedings27Item 1A.Risk Factors27Item 2.Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities27Item 5.Other Information27Item 6.Exhibits28Signatures29 PART I—FINANCIAL INFORMATION CARIBOU BIOSCIENCES, INC. AND ITS SUBSIDIARIESCondensed Consolidated Balance Sheets(Unaudited)(in thousands, except share and per share amounts) CARIBOU BIOSCIENCES, INC. AND ITS SUBSIDIARIESCondensed Consolidated Statements of Operations and Comprehensive Loss(Unaudited)(in thousands, except share and per share amounts) CARIBOU BIOSCIENCES, INC. AND ITS SUBSIDIARIESCondensed Consolidated Statements of Stockholders’ Equity(Unaudited)(in thousands, except share amounts) CARIBOU BIOSCIENCES, INC. AND ITS SUBSIDIARIESCondensed Consolidated Statements of Cash Flows(Unaudited)(in thousands) CARIBOU BIOSCIENCES, INC. AND ITS SUBSIDIARIESNotes to Condensed Consolidated Financial Statements(Unaudited) 1. Description of the Business, Organization, and Liquidity Business and Organization Caribou Biosciences, Inc. (“Company” or “we”) is a clinical-stageClusteredRegularlyInterspacedShortPalindromicRepeats (“CRISPR”) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients withdevastating diseases. Our genome-editing platform is based on our novel chRDNA (CRISPRhybridRNA-DNA, pronounced“chardonnay”) technology, which enables more precise genome editing of allogeneic cell therapies. Our allogeneic, or off-the-shelf,chimeric antigen receptor (“CAR”)-T (“CAR-T”) cell therapy candidates are manufactured in advance with cells from healthy donors,with the goal of enabling broad patient access, rapid patient treatment, and increased manufacturing scale. We use our chRDNAtechnologies to armor our allogeneic CAR-T cell therapies through multiple genome-editing strategies, such as checkpoint disruptionand immune cloaking, to enhance activity against hematologic malignancies. We incorporated in October 2011 as a Delaware corporation and are headquartered in Berkeley, California. We have fourwholly owned subsidiaries that hold interests in our equity investments and do not have operating activities. Liquidity We have incurred operating losses and negative cash flows from operations since our inception and we had an accumulateddeficit of $621.6 million as of March31, 2026. During the three months ended March31, 2026, we incurred a net loss of $25.1 millionand used $27.0 million of cash in operating activities. We expect to continue to incur substantial losses, and our ability to achieve andsustain profitability will depend on the successful development, regulatory approval, and commercialization of our CAR-T cell therapyproduct candidates and on our ability to generate sufficient revenue to support our cost structure. We may never achieve profitabilityand, unless and until we do, we will need to cont